Abstract:
An intraocular lens of novel structure exhibiting an excellent focus adjusting power. A hollow capsule structure is filled with a transparent liquid-like or gel-like filler (32). A front wall of the capsule structure is composed of a flexible lens front film (16), and a rear wall of the capsule structure is composed of an optical lens (18) having a diameter larger than that of the flexible lens front film (16). Under a state inserted into and attached to a capsula lentis, pressure variation of a corpus vitreum acts on the optical lens (18) to enable focal refraction power to be adjusted by utilizing swelling deformation of the lens front film (16).
Abstract:
A Perimeter is provided for designating a perimetry point for an eye to be examined with a fundus image of the eye which has already been provided so as to compensate the individual variation in the position of a blind spot to the maculalutea.
Abstract:
An ophthalmic photographic apparatus comprises a photographic mask for defining a fundus photography range, a photographic stop for eliminating light reflected from an anterior portion of the eye, and a focusing lens for bringing the fundus into focus. The photographic mask and the photographic stop are interlocked and move as one unit relative to the movement of the focusing lens in such a way that with respect to a photographic optical system, the photographic mask is maintained at a position substantially conjugate with an imaging plane of a CCD and the photographic stop is maintained at a position substantially conjugate with an anterior portion of the eye. The CCD is located at the image-side focal plane of the image-formation lens, the mask is located on the object-side focal plane of the focusing lens, and the photographic stop is located on the image-side focal plane of the focusing lens.
Abstract:
An imaging system is provided that is capable of controlling a photographic operation to provide favorable images of a fundus of an eye to be examined. When a normal photographic mode is selected, a single operation of a shutter button causes a single trigger signal to be generated. On the other hand, when a stereo photographic mode is selected, a single operation of a shutter button causes two trigger signals to be generated in succession. The generated trigger signal triggers a switching device so that a position of a photographic stop is automatically switched to a position predetermined for the photographic mode, and the photographic light source is caused to emit light a number of times that corresponds to the selected photographic mode. In such a configuration, fundus images are automatically produced a set number of times by a single operation of the shutter. Therefore, a high-quality fundus image can be obtained without concerns that an appropriate moment to capture an image will be missed.
Abstract:
A compound represented by the following general formula (1), a salt thereof, or an ester thereof: wherein m represents an integer of 0 to 4, n represents an integer of 5 to 9, and R represents hydrogen atom or a protective group of hydroxyl group, which has reducing actions of blood glucose, plasma insulin, and triglyceride, and is useful for preventive and/or therapeutic treatment of diabetes, complications of diabetes, hyperlipemia and others.
Abstract:
Exciting light from a strobe light source is projected onto the fundus of the subject eye to excite a fluorescence substance in a subject eye fundus. Natural fluorescence exited in the fundus is received by a photodiode via a stop located at a position that is conjugate with the fundus. An XY stage is used to move the stop perpendicularly to the optical axis to change the measurement location. The output of the photodiode is used to calculate the intensity of the fluorescence from the measurement location. Since the measurement location can be changed with ease, it is possible to accurately and easily measure natural fluorescence from a desired part of the fundus.
Abstract:
When connecting a blood collecting unit (not shown) with an adaptor, streaming blood in a first inflow passage, and streaming liquid including surfactant or fluorescent dyes in a second inflow passage, the blood and the liquid are mixed at a mixing portion, and platelets, erythrocytes and cell membranes of leukocytes in the blood are dissolved by the surfactant, and the nuclei of the leukocytes are fluorescently stained with the fluorescent dyes. Then, a fluorescent particle counting portion counts the fluorescently stained nuclei of the leukocytes during moving in an outflow passage. According to the invention, a number of leukocytes can be correctly measured with a simple operation, such as connection of a blood collecting unit or the like with the adaptor.
Abstract:
Multiple fundus images are obtained and stored in a memory. The images concern a same eye to be examined, but are obtained at different positions relative to the optical axis of the eyeball. An image playback portion repeatedly displays fundus images from the memory, in order at a predetermined time pitch and as obtained from the different positions. This encompasses a stereoscopic range, using display of the images one-by-one.
Abstract:
The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. 1 (In the formula, 2 is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where Ar is an optionally substituted aryl group; X is nullNHnull, oxygen atom or sulfur atom; Y is nullNR1null, oxygen atom, sulfur atom, sulfoxide or sulfone; Z is a single bond or nullNR2null; R1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; R2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; l is an integer of from 0 to 15; m is an integer of 2 or 3; and n is an integer of from 0 to 3). The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).
Abstract translation:本发明提供新的环状二胺化合物和含有它们的药物组合物。 本发明涉及由式(I)表示的化合物或其盐或溶剂化物。 (式中,是苯,吡啶,环己烷或萘的任意取代的二价残基,或者是亚乙烯基,其中Ar是任意取代的芳基; X是-NH-,氧原子或硫原子; Y是-NR1- ,氧原子,硫原子,亚砜或砜; Z是单键或-NR2-; R 1是氢原子,任选取代的低级烷基,任选取代的芳基或任选取代的甲硅烷基低级烷基; R 2是氢原子, 取代的低级烷基,任选取代的芳基或任选取代的甲硅烷基低级烷基; l为0至15的整数; m为2或3的整数; n为0至3的整数)。 本发明的化合物可用作药物组合物,特别是作为酰基辅酶A胆固醇酰基转移酶(ACAT)的抑制剂。